slides · global inventory
47 Quick Win Big Bet
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,718
Current window 6,061-6,090
Pages 324
Rows per page 30
Loop
6,061-6,090 of 9,718
18
Kaplan-Meier survival curve showing probability of being retreated with IVIg.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
19
The slide uses a central quote to humanize the clinical problem and market opportunity.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
20
The slide uses an infinity-loop style diagram to represent a continuous process or interconnected concepts.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
08
The chart uses a Gantt-style visualization to show the progress of drug candidates through clinical phases.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
09
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
10
The slide uses a visual comparison framework to illustrate the mechanism of action (MOA) of the drug candidate.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
11
The chart uses a dot plot format to show the occurrence of specific GI symptoms over a 29-day study period across different subjects.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
The diagram illustrates a dose escalation study design with combination therapy.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
Data cut date: 15Nov23BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Data cut date: 15Nov23. Pt = Platinum.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
Data table showing safety profile by dose cohort.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The slide highlights a low incidence of immune-related adverse events (2 out of 18 patients).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
This is a classic 'spider plot' or 'swimmer plot' variant used in oncology clinical trials to visualize individual patient tumor burden changes over time.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The chart is a spider plot (or swimmer plot variant) showing change in target lesion size over time for individual patients.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
Before-after medical imaging comparison.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
The slide uses a before-and-after medical imaging comparison to demonstrate drug efficacy.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
The table tracks 3 patients across different cancer types, detailing their age, prior treatments, adverse events, dose-limiting toxicities (DLT), cycles completed, response, and current disposition.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
Crocs | Investor Presentation Deck | 29 slidesCrocs | Investor Presentation Deck | 29 slides · Crocs
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Crocs | Investor Presentation Deck | 29 slidesCrocs | Investor Presentation Deck | 29 slides · Crocs
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
10
The slide uses a four-column process-like layout to describe strategic focus areas.Cytek | Investor Conference Presentation Deck | 16 slides · Cytek
Conference presentation Investor relations Beat · Business ModelLoop · Golden Circle1 hit
15
The slide uses a split-screen layout to contrast past achievements with current research findings.D-Wave | Investor Conference Presentation Deck | 20 slides · D-Wave
Conference presentation Investor relations Beat · Rising SuccessLoop · Quick Win Big Bet1 hit
16
D-Wave | Investor Conference Presentation Deck | 20 slidesD-Wave | Investor Conference Presentation Deck | 20 slides · D-Wave
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
11
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate clinical validation.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
12
The slide uses a side-by-side comparison of two market segments, each with a big number metric and supporting clinical/regulatory context.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
13
Includes a biological diagram illustrating the RAS protein state transition and mutation impact.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
14
The chart shows lower IC50 values for the Q61X mutation group, suggesting higher sensitivity to the drug.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
15
Waterfall plots showing best percentage change from baseline for two distinct patient cohorts.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
16
Includes a Kaplan-Meier survival curve comparing existing standard-of-care options.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
17
The slide uses a 'before-after' visual comparison to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
18
The slide highlights US FDA Fast Track designation and superior PFS performance.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit